Newsletter 14/2025
/in Newsletter/by MaxLAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hi fellow warriors! This week too, there are only a few articles, but they’re very interesting. To fill the space, I wrote longer summaries! But they’re worth reading—new approaches and new clinical trials are on the horizon. Stay strong and fight on! […]
IDOV-Immune A Viral Therapy Turning the Tide Against Cancer
/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1 for TTX-MC138: Breakthrough RNA Therapeutic Advances in Targeting Metastatic Cancers
/in Clinical Trial, Metastatic, Phase 1/by MaxUPDATE On ENV105: Safety Lead-In Completed for This Innovative Therapy
/in Clinical Trial, Metastatic, Phase 2/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 abiraterone abiraterone acetate ADC ADT AI ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T clinical trial crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide HRR immunotherapy mcrpc metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data T-cell therapy theranostics
Latest Posts
- Newsletter 9/2026 March 1, 2026
- CT Muscle Measure Guides Treatment Benefit in New Prostate Cancer: STAMPEDE Findings February 25, 2026
- Igermetostat Plus Enzalutamide Delivers Promising rPFS in Post-Abiraterone mCRPC February 25, 2026
- UPLIFT Trial: Abemaciclib Safely Boosts PSMA for Better Radioligand Therapy in Advanced Prostate Cancer February 25, 2026